Loading data for MIRA — first visit, this takes a few seconds.
MIRA Pharmaceuticals Inc. (MIRA)
NasdaqCM: MIRA
· Precio en tiempo real · USD
0.76
-0.03 (-3.80%)
Al cierre: Aug 18, 2026, 3:59 PM
MIRA Pharmaceuticals Inc. (MIRA) Stock Price, Analysis & Data
-3.80% (1D)
| Precio de compra | 0.55 |
| Capitalización de mercado | 32.13M |
| Ingresos (TTM) | n/a |
| Beneficio neto (TTM) | -31.04M |
| Beta | 1.55 |
| EPS (TTM) | -1.22 |
| Ratio PER (TTM) | n/a |
| Adelante PE | -1.86 |
| P/B (TTM) | 3.44 |
| P/S (TTM) | n/a |
| Earnings Date | n/a |
| Precio de venta | 0.99 |
| Volumen | 40,129 |
| Volumen medio (20D) | 98,893 |
| Abierto | 0.77 |
| Anterior Cerrar | 0.79 |
| Rango del día | 0.76 - 0.79 |
| Rango de 52 semanas | 0.60 - 2.45 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de MIRA
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treatin...
Industria Drug Manufacturers - General
Sector Healthcare
IPO Fecha Aug 3, 2023
Empleados n/a
Bolsa de Valores NasdaqCM
Símbolo bursátil MIRA
Sitio web https://mirapharmaceuticals.com
Desempeño financiero
En 2025, los ingresos de MIRA Pharmaceuticals fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -10.44M, un aumento de 32.98%.
Estados financierosSorpresa de resultados
MIRA Pharmaceuticals ha publicado sus resultados trimestrales en Nov 13, 2025:
